<qa>  What is the STUDY of SAFETY, TOLERABILITY and PLASMA CONA PHASE IIIA STUDY OF SAFETY, TOLERABILITY AND PLASMA CONCENTRATION OF SUBCUTANEOUS CONTINUOUSLY-DELIVERED LEVODOPACARBIDOPA SOLUTION ND0612 IN PD PATIENTS: 